According to the World Health Organisation (WHO) cardiovascular diseases are the principal cause of mortality in the world. In industrialised countries the number of people suffering from such afflictions continues to rise. The hearts of such people are generally unable to pump sufficient blood around the body. Their ability to produce the usual physical effort, even moderate effort, without showing signs of fatigue or breathlessness diminishes alarmingly.
Dr. Peter Langsjoen is a specialist in congestive heart failure. He has been practising in Texas in the area of non-invasive cardiology for some 30 years. He was one of the first, in the early 1980s, to assemble all the clinical results of using Coenzyme Q10 and Ubiquinol in improving cardiac performance. Numerous studies give every reason to believe that micro-nutrient supplements, such as Ubiquinol, are an important factor in successful therapy for such patients.
Supplements - not just beneficial, but essential
The muscles of the heart contain the highest concentration of Ubiquinol in the human body. The quantity of Coenzyme Q10 lessens with age, and this is compounded among patients suffering from various illnesses, or who take certain drugs or are subject to abnormal stress. Energy production in the heart is thus reduced. One has observed that a lack of Coenzyme Q10 in the blood is always found in cases of heart failure, with the degree of such deficiency being correlated with the degree of heart failure. A deficit of energy influences the heart's natural rhythm and vice versa - a weakened heart suffers from a lack of sufficient energy.
One is now fully justified, based on all the studies in this area, in stating that Ubiquinol supplements produce better results than those based on Coenzyme Q10. Dr. Langsjoen first prescribed between 150 and 600 mg of Coenzyme Q10 per day to a group of seven patients in the terminal stage of heart failure (stage IV NYHA). Then he moved to administering a daily dose of between 450 and 900 mg of Ubiquinol. The average values of the Coenzyme Q10 concentrations in the blood plasma were increased by a factor of between three and five - a significant increase - and the ejection rate of the heart’s pumping mechanism went from 22% to 39%. For five of the seven patients, their NYHA (New York Heart Association) classification was visibly improved by one, two and even three stages. (1)
In a subsequent study, Dr. Langsjoen prescribed Ubiquinol instead of the standard Coenzyme Q10 for patients in stages II and III (in the NYHA classification). Even though the quantity of Ubiquinol given was reduced by 50 mg compared with the previously used quantity of Coenzyme Q10 (334 mg instead of 384 mg), the level of Coenzyme Q10 in the blood plasma was almost doubled (2.9 mg/l to 5.3 mg/l) and the patients' NYHA classification was improved - 2.5 to 1.6 (2).
Better results with Ubiquinol
Using food supplements containing Ubiquinol is totally harmless and produces no side effects. This vital substance can be prescribed for people in all stages of the NYHA's classification of heart failure. In particular, Ubiquinol acts faster than the classic Coenzyme Q10 in patients suffering from severe cases of heart failure - in stages III and IV. This is due to the fact that Ubiquinol is between two and four times better assimilated by the organism and therefore more ‘bio-available’. Because of its true active anti-oxidant configuration, Ubiquinol can be directly absorbed by the body, whereas standard Coenzyme Q10 (the oxidised form) needs first to be converted to Ubiquinol before being assimilated by the body. Studies have shown that visibly higher blood levels of Coenzyme Q10 can be achieved using Ubiquinol. The optimum level of Ubiquinol for therapeutic effectiveness needs to be above 3.5 mg/l. Such levels can only be achieved in patients suffering from the more severe forms of heart failure (NYHA III and IV) by administering Ubiquinol since using Coenzyme Q10 is not effective enough.
Indirectly, Ubiquinol can have beneficial effects concerning other cardiovascular risks:
• Diminution in the oxidation of LDL cholesterols (Mohr 1992)
• Reduction in cholesterol production (Schmelzer 2009)
• Reduction of the more atherogenic fractions of LDL cholesterol (Schmelzer 2011)
• Positive influence on the endothelial vessel walls and on blood flow (Gao 2012)
• Lower blood pressure (Rosenfeldt 2005 and 2007, Langsjoen 2009)
• Anti-inflammatory effect (Schmelzer 2011)
1) Peter H. Langsjoen (2008): Supplemental ubiquinol in patients with advanced congestive heart failure. BioFactors 2008; 32; 119-128.
2) Langsjoen PH, Langsjoen AM. (2010) Supplemental Ubiquinol in congestive heart failure – 3 year experience. 6th International Q10 Conference Brussels. May 27-30 2010. Page 29-30.